SCHEMBL4790085

SCHEMBL4790085

CC(C)(C)c1ccc(S(=O)(=O)c2ccc(F)cc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 7/20 0.66
ALDH1A1 P00352 5/20 0.55
MAPT P10636 3/20 0.50
MEN1 O00255 2/20 0.50
NPC1 O15118 2/20 0.50
MAPK1 P28482 2/20 0.50
RAB9A P51151 2/20 0.50
KMT2A Q03164 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
XBP1 P17861 1/20 0.50
HTT P42858 1/20 0.50
LMNA P02545 2/20 0.49
GAA P10253 1/20 0.49
ABCC9 O60706 1/20 0.47
ABCC8 Q09428 1/20 0.47
KCNJ11 Q14654 1/20 0.47
KCNJ8 Q15842 1/20 0.47
NR1I2 O75469 1/20 0.44
GPR183 P32249 1/20 0.44
HSD17B3 P37058 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9360098 0.89 ALDH1A1 (0.67) HSD11B1ALDH1A1MAPTMEN1NPC1
SCHEMBL15383714 0.83 ALDH1A1 (0.59) HSD11B1ALDH1A1MAPTMEN1NPC1
SCHEMBL17998031 0.83 ALDH1A1 (0.59) HSD11B1ALDH1A1MAPTMEN1NPC1
SCHEMBL4328574 0.82 HSD11B1 (0.55) HSD11B1ALDH1A1MEN1MAPK1KMT2A
SCHEMBL30072318 0.82 HSD11B1 (0.55) HSD11B1ALDH1A1MEN1MAPK1KMT2A
SCHEMBL79787 0.82 HSD11B1 (0.55) HSD11B1ALDH1A1MEN1MAPK1KMT2A
SCHEMBL2121770 0.82 HSD11B1 (0.55) HSD11B1ALDH1A1MEN1MAPK1KMT2A
SCHEMBL70544 0.82 SMN1; SMN2 (0.59) HSD11B1ALDH1A1MAPTMEN1NPC1
SCHEMBL7937293 0.81 HSD11B1 (0.58) HSD11B1MEN1NPC1KMT2AABCC9
SCHEMBL24985020 0.81 HSD11B1 (0.47) HSD11B1ALDH1A1MAPTMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170196854-A1 USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS INTERVET INC. (US) 2017-07-13 US disclosed
US-20170196854-A1 USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS INTERVET INC. (US) 2017-07-13 US disclosed
US-9309260-B2 Inhibitors of hepatitis C virus PRESIDIO PHARMACEUTICALS, INC. (US) 2016-04-12 US disclosed
US-9096524-B2 Anthelmintic agents and their use INTERVET INTERNATIONAL B.V. (NL) 2015-08-04 US disclosed
US-9085587-B2 Inhibitors of hepatitis C virus PRESIDIO PHARMACEUTICALS, INC. (US) 2015-07-21 US disclosed
US-20140286899-A1 INHIBITORS OF HEPATITIS C VIRUS PRESIDIO PHARMACEUTICALS, INC. (US) 2014-09-25 US disclosed
US-20130302282-A1 Inhibitors of Hepatitis C Virus PRESIDIO PHARMACEUTICALS, INC. (US) 2013-11-14 US disclosed
US-20120276051-A1 INHIBITORS OF HEPATITIS C VIRUS PRESIDIO PHARMACEUTICALS, INC. (US) 2012-11-01 US disclosed
US-20120276051-A1 INHIBITORS OF HEPATITIS C VIRUS PRESIDIO PHARMACEUTICALS, INC. (US) 2012-11-01 US disclosed
US-20120251497-A1 INHIBITORS OF HEPATITIS C VIRUS PRESIDIO PHARMACEUTICALS, INC. 2012-10-04 US disclosed
US-20120251497-A1 INHIBITORS OF HEPATITIS C VIRUS PRESIDIO PHARMACEUTICALS, INC. 2012-10-04 US disclosed
WO-2012058125-A1 INHIBITORS OF HEPATITIS C VIRUS PRESIDIO PHARMACEUTICALS, INC. (US) 2012-05-03 WO disclosed
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2011-12-29 US disclosed
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2011-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE ACHE, ABCB11, MPO HSD11B1 2791/4885ALDH1A1 864/4885MAPT 1648/4885
US-20120276051-A1 INHIBITORS OF HEPATITIS C VIRUS HAVCR2, LIPC, HCCS HSD11B1 1293/4885ALDH1A1 1654/4885MAPT 3566/4885
US-20170196854-A1 USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS MPO, DHODH, DHX35 HSD11B1 1916/4885ALDH1A1 1001/4885MAPT 2413/4885
US-20130302282-A1 Inhibitors of Hepatitis C Virus HAVCR2, LIPC, HCCS HSD11B1 1293/4885ALDH1A1 1654/4885MAPT 3566/4885
US-20140286899-A1 INHIBITORS OF HEPATITIS C VIRUS HAVCR2, LIPC, HCCS HSD11B1 1293/4885ALDH1A1 1654/4885MAPT 3566/4885
US-20120251497-A1 INHIBITORS OF HEPATITIS C VIRUS HAVCR2, LIPC, HCCS HSD11B1 1293/4885ALDH1A1 1654/4885MAPT 3566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.